Equity
€25,665 from €73,403 in 2021
Equity fell by 65% in 4 years.
CALUMETH
Lifetime
6 annual accounts with figures on one time axispeak €211,212 (2025)
€211,212▲ 19.4%
peak €144,929 (2025)
€144,929▲ 23.4%
peak €73,403 (2021)
€25,665▼ 4.3%
€186,597▲ 10.4%
Board1 name since 2020
1 director
Documentsfilings and deeds
20-07-202611 days before the deadline
2025micro format
Gross margin from €176,874 to €211,212Company renamed from DOCTEUR to CALUMETH 28-03Dividend €146,076Cash from €32,972 to €49,950
Key points
from the 2025 annual accountsTurnover
≈ €420,000 estimated
The micro format states no turnover.
Debts
€186,597 88% of the balance sheet
Financial debts 12%Suppliers 1%Taxes and wages 19%Other 68%
Of this, €164,271 falls due within a year.
Filings
6 annual accounts 1 late
The 2023 accounts came 47 days late. The other five were filed on time.
Starting capital
€2,500 100 shares
Position in the sector
12.1%
Lower solvency than 84% of companies in human health. Sector median 63.1% · 21,322 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,715 companies had the same profile as CALUMETH has now. Each dot stands for 17 companies, two years later.
95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,715 companies, not a prediction for CALUMETH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered office moved within Liège
New registered office: 153 rue du Calvaire 4000 Liège · Previous registered office: Rue Lemille 2-4000 Liège · General meeting of 08-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0755635344
Company renamed from DOCTEUR to CALUMETH
“exercice de la médecine, et en particulier l’activité de médecin anesthésiste” (deed in French) · General meeting of 25-03-2025 · Gazette deed
Incorporation
Founding capital of €2,500, 100 shares · Founder: · Appointment: (director) · published on 06-10-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CALUMETH Liège | €212,262 | €211,212 | 12.1% | - |
| DOCTEURS LEDUC KESTEMAN Liège | €178,546 | €215,654 | 3.7% | - |
| DOTODOC Genk | €203,786 | €218,134 | 30.4% | - |
| DR. NELE BOLLEN Izegem | €232,430 | €221,604 | 74.7% | - |
| DR. AUDREY MEIER, HUISARTS Maaseik | €215,604 | €194,221 | 42.0% | - |
| Dr. Steven Tokarek, huisarts Houthalen-Helchteren | €225,253 | €197,347 | 94.2% | 0.7 |
| DR. JENS ANDRÉ, HUISARTS-SPORTARTS Denderleeuw | €215,201 | €231,322 | 1.9% | - |
These companies have the same main activity as CALUMETH: general medical practice (NACE 86210). They are comparable in size and age: total assets between €179,000 and €232,000, founded between 2020 and 2021.
Official details
Source: KBO- Status
- Active since 02-10-2020Normal situation
- Activity
- General medical practiceNACE 86210and 1 other
- Establishment unit
- 2.308.421.9354000 Liège, since 02-10-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 08-12-2025
Annual accounts 2025
- €212,262▲ 8.4%
- Filing
- Filed on 20-07-2026, 11 days before the end of the filing period
Insights on CALUMETH
CALUMETH files the micro format. That format states no turnover. The gross margin rose from €27,106 in 2020 to €211,212 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CALUMETH
- What is the company number of CALUMETH?
- The company number of CALUMETH is 0755.635.344. The VAT number is the same number with BE in front: BE 0755.635.344.
- Where is CALUMETH based?
- The registered office is at Rue du Calvaire 153, 4000 Liège.Company details
- What does CALUMETH do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of CALUMETH?
- CALUMETH is a private limited company (BV).
- When was CALUMETH founded?
- CALUMETH was founded on 02-10-2020.
- Is CALUMETH still active?
- Yes, CALUMETH is an active enterprise in the KBO register.
- What is the turnover of CALUMETH?
- The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €211,212 and 64 comparable companies (NACE 862). It probably lies between €320,000 and €530,000.Financials
- Is CALUMETH profitable?
- In financial year 2025, CALUMETH made a profit of €144,929.
- Where can I find the annual accounts of CALUMETH?
- CALUMETH filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CALUMETH due?
- CALUMETH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.